My mistake the high dose is on-par or a bit better then NKTR-118 but they had a higher placebo response. Here is a link to the poster if anyone wants to do cross-trial comparisons and be shunned by non-investors nektar.com/pdf/pipeline/NKTR-118/Nektar_poster118AAPM.pdf
Just to be absolutely clear on the ADLR data, their SBMs are the number per week, correct, and not total number over 4 week period? I believe they refer to primary endpoint being weekly SBMs but when they disclose the actual number in the PR they don't specifically say that it's a per week number. I'm probably reading too much into that. Also, high dose for ADLR drug is 3.4 SBMs (presumably per week) compared to 4.4 SBMs/week for NKTR high dose (50 mg). I think you said before NKTR isn't moving that dose forward but the 25mg dose still produced 3.6 SBMs/week, which is still a tad better than the ADLR drug.